



Medco Cypress Tree Pte. Ltd.

(incorporated with limited liability under the laws of Singapore)

PRICING OF US\$200,000,000 8.625% SENIOR NOTES DUE 2030 TO BE CONSOLIDATED AND FORM A SINGLE CLASS WITH THE EXISTING US\$400,000,000 8.625% SENIOR NOTES DUE 2030 OF MEDCO CYPRESS TREE PTE. LTD. ISSUED ON 19 MAY 2025

Medco Cypress Tree Pte. Ltd. (the “**Issuer**”) wishes to announce that it has priced US\$200,000,000 aggregate principal amount of 8.625% Senior Notes due 2030 (the “**Notes**”) to be consolidated and form a single class with its existing US\$400,000,000 aggregate principal amount of the 8.625% Senior Notes due 2030 issued on 19 May 2025.

The Notes will be issued at an issue price of 103.072% of their principal amount, plus accrued interest from (and including) 19 November 2025 to (but excluding) the issue date of the Notes. The Notes are expected to be issued on or about 15 April 2026.

Approval in-principle has been received from the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) for the listing and quotation of the Notes on the Official List of the SGX-ST. The SGX-ST assumes no responsibility for the correctness of any of the statements made or opinions expressed or reports contained herein. Admission to the Official List of the SGX-ST and quotation of the Notes on the SGX-ST is not to be taken as an indication of the merits of the Issuer, its subsidiaries, its associated companies or the Notes. The Notes are expected to be listed on the SGX-ST on or about 16 April 2026.

Medco Cypress Tree Pte. Ltd.

(UEN/Company Registration No. 202512442H)

9 April 2026

This announcement is not for distribution in the United States or to any U.S. persons (as defined under the Securities Act). The Notes referred to herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”) or with any securities regulatory authority of any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, into the United States unless the Notes referred to herein are so registered or an exemption from the registration requirements is available. There will be no public offering of the Notes referred to herein in the United States. Accordingly, the Notes described herein will be offered and sold only outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act. Nothing in this communication shall constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This announcement does not constitute a public offering in Indonesia under Law Number 8 of 1995 regarding Capital Market as amended by Law No. 4 of 2023 on Development and Strengthening of Financial Sectors as amended by Law No. 1 of 2026 on the Adjustment of Criminal Penalties and its implementing regulations (the “**Indonesian Capital Market Law**”). The issuance of the Notes does not constitute (i) a public offering in Indonesia under the Indonesian Capital Market Law and (ii) a private placement of debt securities under OJK Regulation No. 30/POJK.04/2019 on the Issuance of Debt-Linked Securities and/or Sukuk issued by way of Private Placement and its implementing regulations. The Notes may not be offered or sold in Indonesia or to Indonesian nationals, wherever they are domiciled, or to Indonesian residents, in a manner that constitutes a public offering or private placement of debt securities under the laws and regulations of Indonesia.